Yu-San Kao, Panagiota Mamareli, Ayesha Dhillon-LaBrooy, Philipp Stüve, Gloria Janet Godoy, Lis Noelia Velasquez, Verena K. Raker, Beate Weidenthaler-Barth, Fatima Boukhallouk, Francesca Rampoldi, Luciana Berod, Tim Sparwasser
- Psoriasis is a chronic inflammatory skin disease driven by the IL-23/IL-17 axis. It results from excessive activation of effector T cells, including T helper (Th) and cytotoxic T (Tc) cells, and is associated with dysfunctional regulatory T cells (Tregs). Acetyl-CoA carboxylase 1 (ACC1), a rate-limiting enzyme of fatty acid synthesis (FAS), directs cell fate decisions between Th17 and Tregs and thus could be a promising therapeutic target for psoriasis treatment. Here, we demonstrate that targeting ACC1 in T cells by genetic ablation ameliorates skin inflammation in an experimental model of psoriasis by limiting Th17, Tc17, Th1, and Tc1 cells in skin lesions and increasing the frequency of effector Tregs in skin-draining lymph nodes (LNs).
